Ann: Appendix 4E and Audited 2016 Financial Report-MXC.AX, page-2

Some interesting facts coming out of this or at least nicely documented and not sure if has been mentioned previously.

The white paper with the USyd business school looks like a good off-sided benefit for all cannabis companies in Australia, giving a value to potential medical cannabis market in Australia and provides a good talking point for the industry as a whole.

The assets liabilities ratio is looking good with $8million in cash with loss previous year of $6million so we have a decent amount of money to stretch us through the next financial year. That coupled with expected revenue from the derma product lines
"The Californian distribution deal’s first-year contract is worth approximately €1.2m and the Company expects further revenue uplift in the year ahead."